SMi announces the 16th annual Generics and Patent Strategies London

SMi is pleased to announce the 16th annual Generics and Patent Strategies conference taking place in London from 13-14 May 2013. The conference will see world-renowned experts present the hottest topics and key challenges faced within the industry
Generics and Patent Strategies
Generics and Patent Strategies
Feb. 6, 2013 - PRLog -- In combination with panel discussions, this event will provide the latest updates on increasing profitability in a highly competitive market, how to overcome some of the IP issues faced when challenging patents and takes a detailed look at the pricing pressures surrounding an already saturated marketplace.

SMi is delighted to confirm Paul Csiszar, Director, Basic Industries, Manufacturing and Agriculture, European Commission as one of the speakers of the upcoming event.

He will address the essential tools for commercialisation regarding he the recent developments in antitrust enforcement in the pharma sector. He will look closely at the overview of the commission’s current enforcement activities, update on the patent settlement monitoring and interaction between regulatory and competition issues.

Delegates will be given a comprehensive overview of different strategies involved in regulatory affairs and how these can work to your advantage in Europe, there will be a discussion on how originator companies are protecting their compounds and how you can strategically navigate around these issues, how to identify ways to obtain a foothold in the Marketplace over your competitors: are value added Generics or Biosimilars the answer? Also how Patent litigation can work to your advantage when launching a first to market Generic, and to determine the impacts of “Big Pharma” launching Generics into the Marketplace and what this means for smaller Generics companies

For full conference programme and further information visit or contact Jonathan Collins on +44 0 207 827 6734 or email on
Source:SMi Group
Email:*** Email Verified
Tags:Generics, Biosimilars, Drugs, Pharmacovigilance
Account Email Address Verified     Disclaimer     Report Abuse
SMi Group Ltd. News
Daily News
Weekly News

Like PRLog?
Click to Share